Search
Loading Complete
Mark Sulkowski

Mark Sulkowski, MD

Infectious Diseases

Accepting New Patients
Online Booking
Johns Hopkins Affiliations:
  • Johns Hopkins School of Medicine Faculty

Languages

  • English

14 Insurances Accepted

View all

Gender

Male

About Mark Sulkowski

Professional Titles

  • Senior Associate Dean for Clinical Trials
  • Chief, Division of Infectious Diseases Johns Hopkins Bayview Medical Center
  • Medical Director, Viral Hepatitis Center
  • Director, Office of Clinical Trials

Primary Academic Title

Professor of Medicine

Background

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center.  He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine.

Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection.  He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus.   He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017).

Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA).  With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers.  As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries. 

Centers and Institutes

Clinical Trial Keywords

hepatitis B; hepatitis C

Videos

Recent News Articles and Media Coverage

Lab Website

Mark Sulkowski Lab - Lab Website

  • Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.

Research Summary

An infectious disease expert, Dr. Sulkowski has been the principal investigator for numerous clinical trials related to the management of viral hepatitis, including novel agents. He is the Chair of the Hepatitis Transformative Sciences Group, National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.

Google Scholar

http://scholar.google.com/citations?user=2B2VtN0AAAAJ&hl=en

PubMed

http://www.ncbi.nlm.nih.gov/pubmed/?term=sulkowski+m+or+sulkowski+ms

Selected Publications

  • Balagopal A, Barin B, Quinn J, Rogers R, Sulkowski MS, Stock PG. “Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons.” PLoS One. 2015 Aug 27;10(8):e0135882. doi: 10.1371/journal.pone.0135882. eCollection 2015

  • Lawitz E, Jacobson IM, Nelson DR, Zeuzem S, Sulkowski MS, Esteban R, Brainard D, McNally J, Symonds WT, McHutchison JG, Dieterich D, Gane E. “Development of sofosbuvir for the treatment of hepatitis C virus infection.” Ann N Y Acad Sci. 2015 Jul 31. doi: 10.1111/nyas.12832. [Epub ahead of print]

  • Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. “Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.” N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21

  • Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. “Extrahepatic morbidity and mortality of chronic hepatitis C.” Gastroenterology. 2015 Aug 28. pii: S0016-5085(15)01203-2. doi: 10.1053/j.gastro.2015.08.035. [Epub ahead of print] Review

  • Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. “Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.” Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9

Honors

  • Elected Member, Association of American Physicians, 1/1/18
  • Elected Member, American Society for Clinical Investigation (ASCI), 1/1/11
  • Alpha Omega Alpha, Temple University School of Medicine, 1/1/91

Memberships

  • American Association for the Study of Liver Diseases
  • European Association for the Study of the Liver
  • Infectious Diseases Society of America

Locations

  1. Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
    • 10751 Falls Road, Falls Concourse STE 412, Lutherville, MD 21093
    • The Johns Hopkins Hospital
      • 1717 East Monument Street, Park Building, Ground Level, Baltimore, MD 21287

      Expertise

      Education

      Johns Hopkins University School of Medicine

      Fellowship, Infectious Diseases, 1998

      Duke University Hospital

      Residency, Internal Medicine, 1995

      Temple University School of Medicine

      Medical Education, MD, 1992

      Board Certifications

      Infectious Disease

      American Board of Internal Medicine, 1997

      Internal Medicine

      American Board of Internal Medicine, 1995

      Insurance

      Johns Hopkins providers accept various commercial health insurance plans. However, they may not be included in all of an insurance company's plans or offerings. This may include Exchange, Medicaid, Medicare, and specific limited benefit plans. Exceptions to participation also exist based on your employer’s benefits package and the provider's location or specialty. Please contact your insurer directly to make sure your doctor is covered by your plan. For more details, please review our Insurance Information.
      Search plans
      • Aetna
      • CareFirst
      • Cigna
      • First Health
      • Geisinger Health Plan
      • HealthSmart/Accel
      • Humana
      • Johns Hopkins Health Plans
      • MultiPlan
      • Pennsylvania's Preferred Health Networks (PPHN)
      • Point Comfort Underwriters
      • Private Healthcare Systems (PHCS)
      • UnitedHealthcare
      • Veteran Affairs Community Care Network (Optum-VACCN)